Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Core Insights - Perspective Therapeutics, Inc. is advancing its clinical programs in radiopharmaceuticals aimed at cancer treatment, with a focus on neuroendocrine tumors, melanoma, and solid tumors [2][24][25] Clinical Highlights - The company is conducting a multi-center, open-label study of [Pb]VMT-α-NET targeting SSTR2-positive neuroendocrine tumors, with interim data presented at major medical conferences [3][4][7] - Updated interim results show a favorable safety profile for [Pb]VMT-α-NET, with no dose-limiting toxicities reported and 80% of patients remaining progression-free [8][9] - Cohort 3 of the [Pb]VMT-α-NET study opened in June 2025, with patients receiving up to four doses every eight weeks [9][10] Financial Summary - As of September 30, 2025, the company had approximately $174 million in cash and short-term investments, down from $227 million at the end of 2024, which is expected to fund operations into late 2026 [7][16][17] - Research and development expenses increased by approximately 69% year-over-year for Q3 2025, totaling $20.3 million, primarily due to increased clinical activities and personnel costs [20] - The net loss for Q3 2025 was $26 million, or $0.35 per share, compared to a net loss of $15.1 million, or $0.21 per share, for the same period in 2024 [23][30] Operational Developments - The company has transitioned its operations to focus on continuing operations following the divestiture of its brachytherapy segment in April 2024 [18] - The company is also developing complementary imaging diagnostics to enhance treatment personalization and optimize patient outcomes [24] Future Outlook - The company anticipates sharing updates on its clinical-stage medicines throughout 2026, with strong patient recruitment and clinical site engagement [7][11] - Plans are in place to submit data from ongoing studies to medical conferences in the coming year [11][12]